REG - CRISM Therapeutics - Notice of Interim Results and IMC Presentation

CRISM TherapeuticsAnnouncement

12/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250912:nRSL0414Za&default-theme=true

RNS Number : 0414Z  CRISM Therapeutics Corporation  12 September 2025

 

12 September 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Notice of Interim Results and Presentation via Investor Meet Company

 

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery
company focused on the localised and sustained delivery of chemotherapy drugs,
will announce its Interim Results for the six months ended 30 June 2025 on
Monday 15 September 2025.

Following the results announcement, Andrew Webb, CEO of CRISM Therapeutics,
will host a live presentation via Investor Meet Company on Tuesday 16
September 2025 at 12.00pm BST. The presentation will include Garth
Cruickshank, Emeritus Professor of Neurosurgery at University of Birmingham
and Queen Elizabeth Hospital Birmingham.

Professor Cruickshank, a member of CRISM's Scientific Advisory Board, will
discuss the Company's upcoming Phase 2 trial of irinotecan-ChemoSeed in
glioblastoma, including the early stage work leading up to the start of the
Phase 2 trial.

The Investor Meet Company presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via the Investor Meet
Company dashboard up until 9.00am BST on 15 September 2025 or at any time
during the live presentation.

Investors can sign up, free of charge, to Investor Meet Company and add to
meet CRISM Therapeutics via:
https://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor
(https://urldefense.com/v3/__https:/www.investormeetcompany.com/crism-therapeutics-corporation/register-investor__;!!H_q-o1I4kFo!m0g5hhYxGwEivzj-oSefT-XE3-neHGcysSzlo0seYqtPGgpUC6cLqeKLHZuHw6nmh0MYjC9kjvFgcGrIwrO1UYT4JDPcuKului4IdllYqDg$)

Investors who already follow the Company on the Investor Meet Company platform
will automatically be invited.

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Vadim Alexandre                   CRISM@buchanancomms.co.uk

                                 Adam Cowl
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local and sustained delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This ensures that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of
irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1
2026.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

The Company's LEI is 213800XFW6MKVCHHPW88.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQFLFFEKLEBBE